ACLARIS THERAPEUTICS INC (ACRS) Forecast, Price Target & Analyst Ratings

NASDAQ:ACRS • US00461U1051

Current stock price

3.9 USD
-0.14 (-3.47%)
At close:
3.97 USD
+0.07 (+1.79%)
After Hours:

Analyst forecast overview

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for ACLARIS THERAPEUTICS INC (ACRS).

Forecast Snapshot

Consensus Price Target

Price Target
$8.35
+ 114.13% Upside
→ Price target details

Next Earnings Forecast

Earnings Estimate
Release Date
May 6, 2026
Period
Q1 / 2026
EPS Estimate
-$0.16
Revenue Estimate
1.223M
→ Full earnings forecast details

ChartMill Buy Consensus

Rating
85.33%
Weighted Analyst Rating Score
→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target
$8.35
Upside
+ 114.13%
From current price of $3.90 to mean target of $8.35, Based on 15 analyst forecasts
Low
$3.03
Median
$7.40
High
$16.80

Price Target Revisions

1 Month
2.34%
3 Months
6.79%

Price Target Summary

15 Wall Street analysts provided a forecast for the next 12 months for ACRS. The average price target is 8.35 USD. This implies a price increase of 114.13% is expected in the next year compared to the current price of 3.9.
The average price target has been revised upward by 6.79% in the past 3 months.
→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

ACRS Current Analyst RatingACRS Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 2 4 6

Analyst Ratings History

ACRS Historical Analyst RatingsACRS Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -19 -17 -15 -13 -11 -9 -7 -5 -3 -1 5 10

Analyst Ratings Consensus

ChartMill Buy Consensus
85.33%
ACRS was analyzed by 15 analysts. The buy percentage consensus is at 85. So analysts seem to be very confident about ACRS.
In the previous month the buy percentage consensus was at a similar level.
ACRS was analyzed by 15 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

DateFirmActionFrom → To
2026-03-31WedbushReiterate Outperform -> Outperform
2026-03-19HC Wainwright & Co.Reiterate Buy -> Buy
2026-01-28HC Wainwright & Co.Reiterate Buy -> Buy
2026-01-21HC Wainwright & Co.Reiterate Buy -> Buy
2025-10-20HC Wainwright & Co.Reiterate Buy -> Buy
2025-06-25HC Wainwright & Co.Reiterate Buy -> Buy
2025-05-28WedbushInitiate Outperform
2025-05-14HC Wainwright & Co.Maintains Buy -> Buy
2025-05-09ScotiaBankMaintains Sector Outperform -> Sector Outperform
2025-03-18Cantor FitzgeraldReiterate Overweight -> Overweight
2025-03-07ScotiaBankInitiate Sector Outperform
2024-12-23HC Wainwright & Co.Upgrade Neutral -> Buy
2024-11-19Leerink PartnersUpgrade Market Perform -> Outperform
2024-11-19BTIGUpgrade Neutral -> Buy
2024-11-19JefferiesUpgrade Hold -> Buy
2024-11-18Piper SandlerUpgrade Neutral -> Overweight
2024-09-17HC Wainwright & Co.Reiterate Neutral
2024-08-19HC Wainwright & Co.Reiterate Neutral
2024-07-22HC Wainwright & Co.Reiterate Neutral
2024-01-22HC Wainwright & Co.Downgrade Buy -> Neutral
2024-01-11BTIGDowngrade Buy -> Neutral
2023-12-29HC Wainwright & Co.Reiterate Buy -> Buy
2023-12-18StifelMaintains Hold -> Hold
2023-11-14Cantor FitzgeraldDowngrade Overweight -> Neutral
2023-11-14HC Wainwright & Co.Maintains Buy -> Buy

Next Earnings Forecast Details

Next Earnings Details

Release Date
May 6, 2026
Period
Q1 / 2026
EPS Estimate
-$0.16
Revenue Estimate
1.223M
Revenue Q2Q
-15.95%
EPS Q2Q
-33.57%
Number of Analysts
9

Next Earnings Revisions

Revenue (1 Month)
0.00%
Revenue (3 Months)
-47.87%
EPS (1 Month)
0.90%
EPS (3 Months)
-14.28%

Next Earnings Summary

ACRS is expected to report earnings on 5/6/2026. The consensus EPS estimate for the next earnings is -0.16 USD and the consensus revenue estimate is 1.22M USD.
The next earnings revenue estimate has been revised downward by 47.87% in the past 3 months. Downward revisions are a negative sign and indicate that analysts are more pessimistic about the next earnings compared to 3 months ago.
→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates 2026 - 2033

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033
Revenue
YoY % growth
ACRS revenue by date.ACRS revenue by date.
31.249M
5.04%		18.72M
-40.09%		7.826M
-58.19%		5.141M
-34.31%		5.359M
4.24%		5.055M
-5.67%		41M
711.08%		132.8M
223.90%		81.09M
-38.94%		237.66M
193.08%		378.62M
59.31%
EBITDA
YoY % growth
ACRS ebitda by date.ACRS ebitda by date.
-88.551M
-4.98%		-51.52M
41.82%		-75.921M
-47.36%		-83.36M
-9.80%		N/AN/AN/AN/AN/AN/AN/A
EBIT
YoY % growth
ACRS ebit by date.ACRS ebit by date.
-89.414M
-5.01%		-52.327M
41.48%		-76.375M
-45.96%		-86.599M
-13.39%		-101.461M
-17.16%		-127.24M
-25.41%		-127.381M
-0.11%		-131.703M
-3.39%		-157.794M
-19.81%		-31.62M
79.96%		51.153M
261.77%
Operating Margin
ACRS operating margin by date.ACRS operating margin by date.
-286.13%-279.52%-975.91%-1,684.48%-1,893.27%-2,517.11%-310.69%-99.17%-194.59%-13.30%13.51%
EPS
YoY % growth
ACRS eps by date.ACRS eps by date.
-1.25
6.02%		-1.51
-20.80%		-0.53
64.90%		-0.65
-22.67%		-0.68
-3.93%		-0.82
-21.07%		-0.89
-9.31%		-0.46
48.29%		-0.73
-58.84%		0.28
137.50%		1.10
300.00%

All data in USD

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

Q1 / 26 Q2 / 26 Q3 / 26 Q4 / 26 Q1 / 27 Q2 / 27 Q3 / 27 Q4 / 27
EPS
Q2Q % growth		-0.16
-33.57%		-0.16
-23.97%		-0.15
-27.50%		-0.14
10.93%		-0.16
-0.12%		-0.16-0.17
-9.11%		-0.21
-45.78%
Revenue
Q2Q % growth		1.223M
-15.95%		1.231M
-30.73%		1.238M
-62.47%		1.26M
-2.70%		1.301M
6.38%		1.326M
7.72%		1.403M
13.33%		1.403M
11.35%
EBITDA
Q2Q % growth		N/AN/AN/AN/AN/AN/AN/AN/A
EBIT
Q2Q % growth		-21.744M
-20.24%		-21.765M
-18.24%		-21.907M
-27.75%		-21.358M
6.05%		N/AN/AN/AN/A

All data in USD

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

ACRS Yearly Revenue VS EstimatesACRS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 100M 200M 300M
ACRS Yearly EPS VS EstimatesACRS Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 1 -1 -2 -3 -4

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year
-15.57%
EPS Next 5 Year
2.43%

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year
-16.35%
Revenue Next 5 Year
72.73%

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

ACLARIS THERAPEUTICS INC / ACRS Forecast FAQ

Can you provide the average price target for ACLARIS THERAPEUTICS INC stock?

15 analysts have analysed ACRS and the average price target is 8.35 USD. This implies a price increase of 114.13% is expected in the next year compared to the current price of 3.9.

When does ACLARIS THERAPEUTICS INC (ACRS) report earnings?

ACLARIS THERAPEUTICS INC (ACRS) will report earnings on 2026-05-06.

What are the consensus estimates for ACRS stock next earnings?

The consensus EPS estimate for the next earnings of ACLARIS THERAPEUTICS INC (ACRS) is -0.16 USD and the consensus revenue estimate is 1.22M USD.

What is the expected long term growth rate for ACLARIS THERAPEUTICS INC (ACRS)?

The expected long term growth rate for ACLARIS THERAPEUTICS INC (ACRS) is -16.35%.